University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
BRITISH JOURNAL OF HAEMATOLOGY（2018）
关键词
relapsed,refractory DLBCL,MEK inhibition,selumetinib,novel therapies
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要